Product Information

Ku-0063794 is a pyridopyrimidine mTOR inhibitor with anti-tumour activity. It functions as an mTOR inhibitor and antineoplastic agent. It belongs to morpholines, pyridopyrimidines, monomethoxybenzene, tertiary amino compounds, and benzyl alcohols.

CAS No.	938440-64-3
Product Name	Ku-0063794

Heavy Atom Count	34	Rotatable Bond Count	5
Atom Stereo Count	2	Bond Stereo Count	0
HBA	9	HBD	1
TPSA	93.070 Å²	Charge	0
Exact Mass	465.23760	Complexity	1157.50
pKa	11.433	XLogP	2.643

Ku-0063794

CAS No.	938440-64-3
MDL No.	MFCD22666594
MF	C₂₅H₃₁N₅O₄
MW	465.50
InChI Key	RFSMUFRPPYDYRD-CALCHBBNSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	938440-64-3
Product Name	Ku-0063794

Heavy Atom Count	34	Rotatable Bond Count	5
Atom Stereo Count	2	Bond Stereo Count	0
HBA	9	HBD	1
TPSA	93.070 Å²	Charge	0
Exact Mass	465.23760	Complexity	1157.50
pKa	11.433	XLogP	2.643

Ku-0063794

Pricing & Availability

Product Information

Properties

Ku-0063794

Pricing & Availability

Product Information

Properties

Documentation

Ku-0063794

Pricing & Availability

Product Information

Properties

Related Articles

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.

Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).

Similar Products

Vistusertib

Ku-0063794

Pricing & Availability

Product Information

Properties

Related Articles

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.

Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).

Similar Products

Vistusertib

Documentation